Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HCTZ monotherapy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Irbesartan/HCTZ | DRUG | Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks. |
| Irbesartan monotherapy | DRUG | Tablets, Oral, 150 mg, Once daily, 12 weeks. |
| HCTZ monotherapy | DRUG | Tablets, Oral, 12.5 mg, Once daily, 12 weeks. |
Inclusion Criteria: * Willing to provide written informed consent * Subjects must have uncontrolled hypertension defined as: * average systolic blood pressure between 160 mmHg and 180 mmHg (while diastolic blood pressure is less than 110 mmHg) or * average diastolic blood pressure between 100 ...
HCTZ monotherapy is used for the treatment of hypertension, a condition of persistently elevated blood pressure. It is a small molecule drug being developed by Bristol-Myers Squibb Company for this cardiovascular indication.
HCTZ monotherapy is a thiazide diuretic that works by inhibiting sodium reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion, which lowers blood pressure. This mechanism is well-established for hydrochlorothiazide.
HCTZ monotherapy is being developed by Bristol-Myers Squibb Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
HCTZ monotherapy has completed a Phase 3 clinical trial for hypertension. The trial, NCT00095550, was a randomized, double-blind, active-controlled study that has been completed, indicating the drug is in late-stage clinical development.
HCTZ monotherapy has one completed Phase 3 clinical trial, NCT00095550, titled 'Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension.' This trial enrolled 496 participants across the United States, Canada, France, Germany, and Russia.
HCTZ monotherapy refers to the use of hydrochlorothiazide as a single agent. The trial NCT00095550 studied this monotherapy in comparison to combination therapy with irbesartan, but the drug itself is the well-known thiazide diuretic hydrochlorothiazide.